Physician profile
Kevin Bridge
NPI 1679735393
$443.27
in general payments reported to CMS, 2019-2025
14 companies · $67.39 in 2025
The $67.39 reported for 2025 was less than what a typical Plastic Surgery provider received nationally (typical 2025 total: $380).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $178 · 2020: $47.86 · 2021: $34.98 · 2022: $55.13 · 2023: $40.85 · 2024: $18.59 · 2025: $67.39.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $126.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $81.37 | 2019-2020 | |
| Abbvie INC. | $55.50 | 2023-2024 | Alloderm, Strattice Reconstructive Tissue Matrix Bps |
| Endo Pharmaceuticals INC. | $53.06 | 2019-2021 | |
| Polynovo North America LLC | $52.46 | 2025 | Novosorb Btm |
| Acell, INC. | $44.98 | 2019-2020 | |
| Stryker Corporation | $40.47 | 2019 | |
| Mentor Worldwide LLC | $27.39 | 2022 | |
| Endo USA, INC. | $14.93 | 2025 | Xiaflex |
| Axogen | $14.90 | 2019 | |
| Allergan, INC. | $14.61 | 2022 | |
| W. L. Gore & Associates, INC. | $13.88 | 2021 | |
| Ethicon US, LLC | $13.13 | 2022 | |
| Galderma Laboratories, L.P. | $12.65 | 2019 | |
| Kerecis Limited | $3.94 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Bridge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.